Clinical Trials
Budesonide has been evaluated in numerous clinical trials across all development phases, investigating inflammatory respiratory conditions such as asthma, chronic obstructive pulmonary disease, and allergic rhinitis, alongside gastrointestinal disorders like ulcerative colitis and Crohn's disease. Sponsored by pharmaceutical entities and academic institutions including AstraZeneca, Aquilon Pharmaceuticals, and Assiut University, these studies encompass pharmacokinetic profiling, methodology evaluation, and epigenetic assessments. While a major portion of these clinical trials are completed, others remain active or recruiting, reflecting sustained clinical interest in optimizing budesonide formulations.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06860542 | RECRUITING | Pneumonitis; Immune-related Adverse Event |
AHS Cancer Control Alberta |
2026-02-10 | PHASE2 |
| NCT05976802 | NOT_YET_RECRUITING | Ulcerative Colitis |
Bausch Health Americas, Inc. |
2027-06 | PHASE4 |
| NCT07560462 | NOT_YET_RECRUITING | Esophageal Stricture |
Shaare Zedek Medical Center |
2026-05-01 | |
| NCT06855043 | NOT_YET_RECRUITING | Invasive Mechanical Ventilation; Severe Respiratory Distress Syndrome |
University of Wisconsin, Madison |
2026-09 | PHASE1; PHASE2 |
| NCT06429475 | RECRUITING | Asthma |
University of KwaZulu |
2024-06-06 | PHASE3 |
| NCT06076304 | RECRUITING | Sinus Infection; Acute Sinusitis |
Daniel Merenstein |
2023-11-21 | PHASE4 |
| NCT07318350 | NOT_YET_RECRUITING | Moderate Asthma |
Eurofarma Laboratorios S.A. |
2026-10 | PHASE3 |
| NCT07595796 | NOT_YET_RECRUITING | Preserved Ratio Impaired Spirometry (PRISM) |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-06-01 | |
| NCT05562466 | RECRUITING | Asthma |
Novartis Pharmaceuticals |
2023-05-11 | PHASE3 |
| NCT06719622 | ENROLLING_BY_INVITATION | Crohn Disease (CD) |
Medical University of Warsaw |
2024-07-30 | PHASE2; PHASE3 |
| NCT07383402 | NOT_YET_RECRUITING | Chronic Rhinosinusitis (CRS) |
Amin Javer |
2026-03-30 | PHASE3 |
| NCT05509933 | RECRUITING | Engraftment Syndrome |
Henry Ford Health System |
2022-11-09 | PHASE3 |
| NCT06283966 | RECRUITING | COPD (Chronic Obstructive Pulmonary Disease) |
AstraZeneca |
2024-02-21 | PHASE3 |
| NCT07499791 | RECRUITING | Chronic Dacryocystitis |
Beijing Tongren Hospital |
2026-05-01 | PHASE2 |
| NCT06334575 | RECRUITING | Chronic Obstructive Pulmonary Disease |
Maria Joyera Rodríguez |
2025-02-12 | PHASE4 |
| NCT07358234 | ENROLLING_BY_INVITATION | Eosinophilic Esophagitis (EoE) |
Mayo Clinic |
2026-02-04 | EARLY_PHASE1 |
| NCT06471257 | RECRUITING | Asthma |
AstraZeneca |
2024-06-17 | PHASE3 |
| NCT07352488 | NOT_YET_RECRUITING | Allergic Asthma |
Henan University of Traditional Chinese Medicine |
2026-01-15 | |
| NCT07654842 | NOT_YET_RECRUITING | Eosinophilic Asthma; Severe Asthma; Severe Eosinophilic Asthma; Asthma |
Endeavor Health |
2026-07-01 | PHASE4 |
| NCT06597682 | NOT_YET_RECRUITING | Post-acute Sequelae of SARS-COV-2 Infection |
Huashan Hospital |
2025-03 | |
| NCT06895460 | NOT_YET_RECRUITING | Bronchial Asthma |
The First Affiliated Hospital with Nanjing Medical University |
2025-06-20 | PHASE3 |
| NCT06890260 | RECRUITING | Allergic Rhinitis (Disorder); Electroacupuncture; Microneedle Knife |
Pengfei Qiu |
2025-04-11 | |
| NCT06473779 | ACTIVE_NOT_RECRUITING | Severe Asthma |
AstraZeneca |
2024-09-30 | PHASE3 |
| NCT06676319 | ACTIVE_NOT_RECRUITING | Asthma |
Sanofi |
2024-11-07 | PHASE2 |
| NCT01225913 | RECRUITING | Asthma |
Gelb, Arthur F., M.D. |
2007-10 | PHASE4 |
| NCT07073950 | RECRUITING | Chronic Obstructive Pulmonary Disease; Hyperinflation |
AstraZeneca |
2025-11-24 | PHASE4 |
| NCT07156175 | RECRUITING | Microscopic Colitis |
Sanofi |
2025-10-14 | PHASE2 |
| NCT06568445 | NOT_YET_RECRUITING | Bronchial Asthma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2024-08-12 | PHASE4 |
| NCT06837051 | NOT_YET_RECRUITING | Olfactory Dysfunction; Chronic Rhinosinusitis |
Peking University Third Hospital |
2025-03-14 | |
| NCT06422689 | ACTIVE_NOT_RECRUITING | Asthma |
AstraZeneca |
2024-05-10 | PHASE4 |
| NCT06528015 | NOT_YET_RECRUITING | Glomerulonephritis, IGA; Probiotics; Budesonide |
Gang Xu |
2024-07 | PHASE4 |
| NCT07684105 | NOT_YET_RECRUITING | Recessive Dystrophic Epidermolysis Bullosa; Dysphagia; Esophageal Stenosis |
Centre Hospitalier Universitaire de Nice |
2026-07-01 | |
| NCT07030894 | RECRUITING | IgA Nephropathy; Chronic Kidney Disease; Proteinuria |
The First Hospital of Jilin University |
2025-09-01 | PHASE4 |
| NCT03250975 | ACTIVE_NOT_RECRUITING | Intubation Complication |
Vanderbilt University Medical Center |
2017-08-19 | PHASE1; PHASE2 |
| NCT06830109 | RECRUITING | Nasal Obstruction |
Washington University School of Medicine |
2024-10-15 | PHASE2 |
| NCT03803787 | RECRUITING | Radiation Pneumonitis |
Instituto Nacional de Cancerologia de Mexico |
2018-09-01 | PHASE2 |
| NCT05405387 | RECRUITING | Multiple Myeloma; Plasma Cell Leukemia |
University of Utah |
2023-05-03 | PHASE2 |
| NCT06596252 | ACTIVE_NOT_RECRUITING | Eosinophilic Esophagitis |
Dr. Falk Pharma GmbH |
2021-05-21 | PHASE3 |
| NCT04314375 | RECRUITING | Ulcerative Colitis |
Bausch Health Americas, Inc. |
2023-09-29 | PHASE4 |
| NCT06531798 | RECRUITING | Moderate to Severe COPD |
AstraZeneca |
2026-01-30 | PHASE4 |
| NCT07267130 | TERMINATED | Chronic Obstructive Pulmonary Disease |
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. |
2025-11-25 | PHASE1 |
| NCT07528820 | NOT_YET_RECRUITING | CRSwNP; Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis |
St. Paul's Sinus Centre |
2026-07-01 | |
| NCT07433569 | COMPLETED | Asthma |
AstraZeneca |
2026-03-05 | PHASE1 |
| NCT06841406 | RECRUITING | Functional Dyspepsia |
Universitaire Ziekenhuizen KU Leuven |
2024-05-01 | PHASE4 |
| NCT06712407 | RECRUITING | IgA Nephropathy |
Calliditas Therapeutics AB |
2024-12-17 | PHASE4 |
| NCT07270302 | NOT_YET_RECRUITING | Chronic Rhinosinusitis |
Washington University School of Medicine |
2025-12 | PHASE1; PHASE2 |
| NCT07763119 | COMPLETED | Meconium Aspiration Syndrome |
Khyber Teaching Hospital |
2025-11-28 | PHASE3 |
| NCT06502366 | ACTIVE_NOT_RECRUITING | Asthma |
AstraZeneca |
2024-07-22 | PHASE3 |
| NCT05791487 | UNKNOWN | Ulcerative Colitis; Ulcerative Colitis Chronic Mild; Ulcerative Colitis Chronic Moderate |
Wolfson Medical Center |
2023-12-01 | |
| NCT06563102 | COMPLETED | Mild Asthma |
AstraZeneca |
2024-09-11 | PHASE4 |
| NCT06067828 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2023-10-24 | PHASE3 |
| NCT07491991 | COMPLETED | Postoperative Pain; NEBULIZATION; Thyroid Surgery |
Qianfoshan Hospital |
2025-03-02 | PHASE4 |
| NCT06785662 | NOT_YET_RECRUITING | Allergic Rhinitis |
Siriraj Hospital |
2025-02-12 | PHASE4 |
| NCT04342039 | ACTIVE_NOT_RECRUITING | Epigenetic Effects of Intranasal Steroids; Environmental Exposure |
University of British Columbia |
2021-01-07 | PHASE4 |
| NCT06905483 | COMPLETED | COPD; Chronic Obstructive Pulmonary Disease (COPD); Small Airway Disease; Triple Therapy; Lung Function |
Thammasat University |
2025-04-01 | PHASE4 |
| NCT05970263 | WITHDRAWN | COPD |
AstraZeneca |
2024-01-19 | PHASE4 |
| NCT03615742 | UNKNOWN | Exposure to Pollution; Glucocorticoid Resistance |
University of British Columbia |
2018-12-01 | PHASE4 |
| NCT06756243 | NOT_YET_RECRUITING | Allergic Rhinitis |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2025-03-01 | |
| NCT04918953 | NOT_YET_RECRUITING | Outcome |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2021-06-02 | PHASE2 |
| NCT06940700 | NOT_YET_RECRUITING | Asthma |
Guangdong Hengrui Pharmaceutical Co., Ltd |
2025-04 | PHASE2 |
| NCT06027606 | COMPLETED | Healthy |
University of Alberta |
2023-09-01 | PHASE1 |
| NCT05689983 | COMPLETED | Asthma in Children; Nonadherence, Medication |
Washington University School of Medicine |
2022-04-01 | PHASE1; PHASE2 |
| NCT06590740 | COMPLETED | Cough-Variant Asthma |
AstraZeneca |
2024-10-18 | PHASE4 |
| NCT06075095 | COMPLETED | COPD (Chronic Obstructive Pulmonary Disease) |
AstraZeneca |
2024-01-11 | PHASE3 |
| NCT06158893 | UNKNOWN | Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy |
Assiut University |
2024-08 | PHASE4 |
| NCT04193878 | TERMINATED | Pneumonia; Hypoxemia; Acute Respiratory Failure; COVID-19 Pneumonia |
Stanford University |
2020-06-01 | PHASE3 |
| NCT06723756 | COMPLETED | Healthy Participants |
AstraZeneca |
2025-01-23 | PHASE1 |
| NCT06482294 | UNKNOWN | Asthma |
Università degli Studi di Ferrara |
2024-06-18 | PHASE2 |
| NCT05831566 | RECRUITING | Asthma |
Franciscus Gasthuis |
2023-01-31 | PHASE3 |
| NCT07725575 | COMPLETED | Bronchopulmonary Dysplasia (BPD) |
Indonesia University |
2024-11-01 | PHASE4 |
| NCT07081399 | RECRUITING | Dysphagia; Dysphagia Rehabilitation |
Damanhour University |
2024-08-08 | EARLY_PHASE1 |
| NCT06340581 | WITHDRAWN | Healthy |
AstraZeneca |
2024-10-17 | PHASE1 |
| NCT05202262 | COMPLETED | Asthma |
AstraZeneca |
2022-01-12 | PHASE3 |
| NCT06571942 | UNKNOWN | COPD Bronchitis; Pollution Related Respiratory Disorder |
National Institute of Respiratory Diseases, Mexico |
2023-11-15 | PHASE4 |
| NCT06657079 | COMPLETED | ARDS; Prevention and Control |
Damanhour University |
2024-05-01 | PHASE1; PHASE2 |
| NCT02455687 | UNKNOWN | Bronchial Asthma |
Hamad Medical Corporation |
2015-06 | PHASE3 |
| NCT05755906 | COMPLETED | Asthma |
AstraZeneca |
2023-02-27 | PHASE3 |
| NCT05555290 | COMPLETED | Asthma |
AstraZeneca |
2022-09-28 | PHASE3 |
| NCT05214599 | WITHDRAWN | Eosinophilic Esophagitis |
Bazell Pharma AG |
2021-04-23 | PHASE2 |
| NCT04233190 | COMPLETED | Asthma Copd |
Eurofarma Laboratorios S.A. |
2023-04-19 | PHASE3 |
| NCT06595121 | COMPLETED | Healthy |
Unither Pharmaceuticals, France |
2024-08-13 | PHASE1 |
| NCT06514157 | COMPLETED | Healthy Volunteer |
AstraZeneca |
2024-08-19 | PHASE1 |
| NCT04545866 | ACTIVE_NOT_RECRUITING | Bronchopulmonary Dysplasia (BPD); Respiratory Distress Syndrome; Prematurity; Extreme; Neonatal |
NICHD Neonatal Research Network |
2021-04-01 | PHASE3 |
| NCT06367881 | UNKNOWN | Neonatal Respiratory Distress Syndrome; Inflammatory Response; Premature Lungs; Neutrophil Extracellular Trap Formation; Preterm Birth |
Ain Shams University |
2022-08-18 | PHASE1 |
| NCT04294641 | COMPLETED | Chronic GVHD |
National Cancer Institute (NCI) |
2021-05-10 | PHASE2 |
| NCT06297668 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2024-04-29 | PHASE1 |
| NCT04727424 | UNKNOWN | Covid19; SARS-Associated Coronavirus |
Cardresearch |
2021-01-19 | PHASE3 |
| NCT06139991 | COMPLETED | Heathy Participants |
AstraZeneca |
2023-11-16 | PHASE1 |
| NCT06858423 | COMPLETED | Nasal Allergy |
Benha University |
2023-08-15 | PHASE4 |
| NCT05573464 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2022-09-27 | PHASE3 |
| NCT07804303 | COMPLETED | Asthma; Chronic Obstructive Pulmonary Disease (COPD) |
Shanghai Xin Huanghe Pharmaceutical Co., Ltd. |
2024-01-13 | PHASE1 |
| NCT06080945 | UNKNOWN | Asthma in Children |
Shaoxing Maternity and Child Health Care Hospital |
2022-01-04 | |
| NCT05325489 | UNKNOWN | Snoring; Mouth Breathing |
Second Xiangya Hospital of Central South University |
2022-04 | PHASE3 |
| NCT05444543 | COMPLETED | Eosinophilic Esophagitis |
University Hospitals Cleveland Medical Center |
2021-11-17 | PHASE4 |
| NCT05322707 | COMPLETED | Asthma |
Cipla Ltd. |
2022-04-15 | PHASE3 |
| NCT04191447 | UNKNOWN | Asthma |
EMS |
2022-07-22 | PHASE3 |
| NCT04422275 | WITHDRAWN | Anosmia |
Washington University School of Medicine |
2021-06-01 | PHASE2 |
| NCT05341401 | UNKNOWN | Ulcerative Colitis Chronic |
Assiut University |
2022-06 | PHASE2; PHASE3 |
| NCT04191434 | UNKNOWN | Asthma |
EMS |
2022-07-22 | PHASE3 |
| NCT04952389 | COMPLETED | Olfactory Dysfunction; COVID-19 |
Mayo Clinic |
2021-12-07 | |
| NCT05569421 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2022-10-11 | PHASE1 |
| NCT05477108 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2022-07-29 | PHASE1 |
| NCT05269030 | UNKNOWN | Parosmia |
Menoufia University |
2022-07 | PHASE2 |
| NCT05269017 | UNKNOWN | Parosmia |
Menoufia University |
2022-06 | PHASE2 |
| NCT05534685 | UNKNOWN | Respiratory Tract Diseases |
Coordinación de Investigación en Salud, Mexico |
2022-09-20 | |
| NCT06268301 | COMPLETED | Healthy Volunteers |
Takeda |
2023-02-06 | PHASE1 |
| NCT05931744 | COMPLETED | Chronic Rhinosinusitis With Nasal Polyps |
Kafrelsheikh University |
2021-05-01 | PHASE2; PHASE3 |
| NCT05364385 | UNKNOWN | Infant, Extremely Premature; Acute Lung Injury; Chronic Lung Disease of Prematurity; Budesonide |
University of Arizona |
2019-12-02 | PHASE4 |
| NCT04675463 | UNKNOWN | Pulmonary Disease, Chronic Obstructive |
ShiYue Li |
2020-12-30 | |
| NCT04964414 | TERMINATED | Dysosmia; Anosmia; Covid19 |
Amanda Stapleton |
2021-09-30 | PHASE1; PHASE2 |
| NCT04933383 | COMPLETED | Asthma |
Aquilon Pharmaceuticals S.A. |
2021-07-23 | PHASE1; PHASE2 |
| NCT05474924 | UNKNOWN | CRS; Polyp, Nasal |
Kafrelsheikh University |
2022-08-01 | PHASE4 |
| NCT05541419 | UNKNOWN | Chronic Rhinosinusitis (Diagnosis) |
Universidade Estadual de Londrina |
2018-08-10 | |
| NCT03275415 | COMPLETED | Respiratory Distress Syndrome; Bronchopulmonary Dysplasia |
Taipei Medical University |
2019-07-01 | PHASE4 |
| NCT03999008 | UNKNOWN | Esophageal Atresia; Anastomotic Stenosis |
St. Justine's Hospital |
2020-06-01 | |
| NCT05341401 | Not yet recruiting | Ulcerative Colitis Chronic |
Assiut University |
2022-06 | Phase 2|Phase 3 |
| NCT04027322 | COMPLETED | Acute Pharyngitis |
Oman Medical Speciality Board |
2019-06-01 | PHASE2; PHASE3 |
| NCT03888131 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2018-07-30 | PHASE3 |
| NCT04163978 | COMPLETED | Chronic Sinusitis |
Sanotize Research and Development corp. |
2019-10-27 | PHASE2 |
| NCT03323866 | TERMINATED | Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis |
Université de Sherbrooke |
2017-05-01 | PHASE3 |
| NCT03245840 | TERMINATED | Eosinophilic Esophagitis (EoE) |
Shire |
2017-10-05 | PHASE3 |
| NCT03083067 | COMPLETED | COPD Exacerbation; Air Pollution |
Peking University First Hospital |
2017-03-20 | |
| NCT04203472 | COMPLETED | Asthma; Cough Variant Asthma |
Medical University of Warsaw |
2019-01-20 | |
| NCT04476628 | WITHDRAWN | Chronic Rhinosinusitis (Diagnosis) |
St. Paul's Hospital, Canada |
2021-02-01 | EARLY_PHASE1 |
| NCT05148312 | COMPLETED | Pharmacokinetics |
Aquilon Pharmaceuticals S.A. |
2021-11-12 | PHASE1 |
| NCT04374474 | WITHDRAWN | Olfactory Disorder |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2021-01-10 | PHASE4 |
| NCT05148312 | Completed | Pharmacokinetics |
Aquilon Pharmaceuticals S.A. |
2021-11-12 | Phase 1 |
| NCT03866538 | TERMINATED | Enteropathy; Celiac Disease; CVID Enteropathy; Collagenous Sprue; Autoimmune Enteropathy |
Mayo Clinic |
2019-09-10 | PHASE4 |
| NCT04215848 | COMPLETED | Asthma |
Hat Yai Medical Education Center |
2020-04-01 | PHASE3 |
| NCT05519514 | COMPLETED | Healthy Subjects; Human Volunteers; Healthy Participants; Bioequivalence |
Abbott |
2021-07-12 | PHASE1 |
| NCT04758078 | UNKNOWN | Respiratory Distress |
Makassed General Hospital |
2021-02-15 | |
| NCT03847896 | COMPLETED | Asthma |
Bond Avillion 2 Development LP |
2019-03-20 | PHASE3 |
| NCT04848662 | COMPLETED | Asthma |
Bond Avillion 2 Development LP |
2021-05-06 | PHASE1 |
| NCT04355637 | COMPLETED | Coronavirus Infection |
Sara Varea |
2020-04-21 | PHASE4 |
| NCT05152355 | COMPLETED | Asthma |
Intech Biopharm Ltd. |
2019-04-22 | PHASE4 |
| NCT03716115 | COMPLETED | Severe Acute Malnutrition |
Queen Mary University of London |
2020-05-04 | PHASE2 |
| NCT02400476 | COMPLETED | Early Stage HER2+ Breast Cancer |
Puma Biotechnology, Inc. |
2015-02 | PHASE2 |
| NCT04267042 | UNKNOWN | Chronic Rhinosinusitis With Nasal Polyps; Allergic Fungal Sinusitis |
St. Paul's Hospital, Canada |
2020-02-03 | EARLY_PHASE1 |
| NCT04416399 | TERMINATED | Coronavirus Infection |
University of Oxford |
2020-07-16 | PHASE2 |
| NCT04342039 | Active not recruiting | Epigenetic Effects of Intranasal Steroids|Environmental Exposure |
University of British Columbia|Genome British Columbia|Johnson & Johnson Consumer Inc. (J&JCI) |
2021-01-07 | Phase 4 |
| NCT03315052 | WITHDRAWN | Acute Cellular Graft Rejection; Liver Transplant Rejection |
Montefiore Medical Center |
2019-01 | PHASE4 |
| NCT04233463 | UNKNOWN | Crohn Disease |
Hillel Yaffe Medical Center |
2020-01 | |
| NCT04078126 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2019-09-10 | PHASE3 |
| NCT03584178 | UNKNOWN | Sinusitis |
St. Paul's Hospital, Canada |
2018-09-05 | |
| NCT04019106 | UNKNOWN | Bronchopulmonary Dysplasia; Respiratory Distress Syndrome in Premature Infant |
University of Manitoba |
2019-10-15 | PHASE1; PHASE2 |
| NCT04854538 | COMPLETED | Healthy |
Genuine Research Center, Egypt |
2020-09-17 | PHASE1 |
| NCT02853578 | SUSPENDED | Asthma |
Ache Laboratorios Farmaceuticos S.A. |
2019-12 | PHASE3 |
| NCT04171180 | UNKNOWN | Cough Variant Asthma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2020-05-01 | PHASE4 |
| NCT04234464 | COMPLETED | Exercise Induced Bronchospasm |
Bond Avillion 2 Development LP |
2020-01-15 | PHASE3 |
| NCT01895075 | WITHDRAWN | Bronchopulmonary Dysplasia |
Dr. Michael Dunn |
2019-01-01 | PHASE2 |
| NCT03412682 | COMPLETED | Colitis, Ulcerative |
Ferring Pharmaceuticals |
2018-03-02 | PHASE3 |
| NCT04331470 | UNKNOWN | COVID-19 |
Fasa University of Medical Sciences |
2020-04-04 | PHASE2; PHASE3 |
| NCT04064684 | TERMINATED | Acute Respiratory Distress Syndrome |
The University of Texas Health Science Center, Houston |
2020-02-04 | PHASE2 |
| NCT03906045 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2019-04-04 | PHASE1 |
| NCT01946711 | COMPLETED | Rhinosinusitis; Chronic Polyposis |
Pari Pharma GmbH |
2013-08-28 | PHASE1; PHASE2 |
| NCT02142634 | COMPLETED | Incomplete Microscopic Colitis |
Dr. Falk Pharma GmbH |
2014-05 | PHASE3 |
| NCT04132570 | COMPLETED | Rhinitis |
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division |
2019-10-22 | PHASE4 |
| NCT03304626 | COMPLETED | Acute Cellular Graft Rejection; New Onset Diabetes After Transplant |
University of Cincinnati |
2017-06-27 | PHASE2 |
| NCT04002349 | UNKNOWN | Determination of the Efficacy of Different Medications for Idiopathic Rhinitis; Impact of Different Medications on Biomarkers of Idiopathic Rhinitis; Safety and Tolerance of Different Medications for Idiopathic Rhinitis |
Beijing Tongren Hospital |
2019-07-01 | |
| NCT04520230 | COMPLETED | COPD |
Tanta University |
2014-10-31 | PHASE4 |
| NCT04016220 | UNKNOWN | Acute Asthma |
University of Monastir |
2019-05-20 | PHASE1 |
| NCT02736409 | COMPLETED | Eosinophilic Esophagitis (EoE) |
Shire |
2016-04-01 | PHASE3 |
| NCT03836677 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2019-02-26 | PHASE3 |
| NCT02972866 | WITHDRAWN | Rhinitis, Allergic, Perennial |
Eurofarma Laboratorios S.A. |
2016-06 | PHASE3 |
| NCT03521063 | UNKNOWN | Bronchopulmonary Dysplasia; Infant,Premature; Respiratory Distress Syndrome |
Hospital Central "Dr. Ignacio Morones Prieto" |
2018-01-01 | PHASE4 |
| NCT00746486 | TERMINATED | Primary Biliary Cirrhosis |
Dr. Falk Pharma GmbH |
2009-02 | PHASE3 |
| NCT03934333 | COMPLETED | Relative Bioavailability |
AstraZeneca |
2019-05-16 | PHASE1 |
| NCT03879590 | UNKNOWN | Asthma Chronic; Asthma in Children |
Universidad Autonoma de Nuevo Leon |
2019-05 | PHASE3 |
| NCT03519061 | WITHDRAWN | Chronic Sinus Infection; Chronic Sinusitis; Chronic Sinusitis - Ethmoidal, Posterior; Chronic Sinus Congestion |
Kaiser Permanente |
2019-08-13 | PHASE2; PHASE3 |
| NCT02972476 | COMPLETED | Chronic Obstructive Pulmonary Disease |
University of Dundee |
2016-12 | PHASE4 |
| NCT02477397 | UNKNOWN | COPD |
University Medical Center Groningen |
2015-05-01 | PHASE3 |
| NCT03369847 | COMPLETED | Asthma; Pediatric ALL |
New York City Health and Hospitals Corporation |
2017-09-10 | PHASE4 |
| NCT03772223 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2019-01-21 | PHASE1 |
| NCT02991768 | TERMINATED | Diarrhea |
University of Kansas Medical Center |
2017-01-27 | PHASE2 |
| NCT01783106 | COMPLETED | Crohn's Disease |
Royal Liverpool University Hospital |
2014-02-01 | PHASE2 |
| NCT03755557 | COMPLETED | Allergic Rhinitis; Allergic Conjunctivitis; Hayfever |
Marinomed Biotech AG |
2018-11-19 | PHASE3 |
| NCT04097613 | COMPLETED | Chronic Rhinosinusitis (Diagnosis) |
St. Paul's Hospital, Canada |
2017-07-28 | EARLY_PHASE1 |
| NCT03478696 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2018-06-25 | PHASE4 |
| NCT03478683 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2018-06-25 | PHASE4 |
| NCT03034005 | COMPLETED | Asthma |
Bispebjerg Hospital |
2017-03-27 | PHASE4 |
| NCT03436225 | UNKNOWN | Bronchiolitis; Respiratory Syncytial Virus |
Assiut University |
2019-02 | PHASE1 |
| NCT02991859 | COMPLETED | Asthma |
GlaxoSmithKline |
2017-02-09 | PHASE2 |
| NCT02493335 | COMPLETED | Eosinophilic Esophagitis |
Dr. Falk Pharma GmbH |
2016-01-15 | PHASE3 |
| NCT03504527 | UNKNOWN | Asthma-COPD Overlap |
Huashan Hospital |
2018-05-01 | |
| NCT03303677 | WITHDRAWN | Chronic Rhinosinusitis (Diagnosis) |
University of Florida |
2018-04-01 | PHASE3 |
| NCT03740373 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
AstraZeneca |
2018-09-04 | PHASE1 |
| NCT01955980 | COMPLETED | Rhinosinusitis |
Pari Pharma GmbH |
2015-10-27 | PHASE1; PHASE2 |
| NCT01821898 | TERMINATED | Eosinophilic Esophagitis |
Baylor College of Medicine |
2013-07-09 | PHASE2 |
| NCT03551197 | UNKNOWN | Pulmonary Disease, Chronic Obstructive; Exercise; Lung Function Decreased; Quality of Life |
Zhujiang Hospital |
2018-06-13 | PHASE4 |
| NCT03563001 | UNKNOWN | Pulmonary Disease, Chronic Obstructive; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Small Airway Disease; Quality of Life |
Zhujiang Hospital |
2018-06-20 | PHASE4 |
| NCT03537326 | COMPLETED | Healthy |
Parc de Salut Mar |
2018-05-22 | PHASE1 |
| NCT01950507 | TERMINATED | Stem Cell Transplantation; Graft vs Host Disease |
National Institutes of Health Clinical Center (CC) |
2014-02-20 | PHASE1 |
| NCT02019758 | COMPLETED | Eosinophilic Esophagitis |
University of North Carolina, Chapel Hill |
2015-01-01 | PHASE4 |
| NCT02002715 | COMPLETED | Eosinophilic Bronchitis |
The First Affiliated Hospital of Guangzhou Medical University |
2008-03 | PHASE4 |
| NCT02907593 | TERMINATED | Bronchopulmonary Dysplasia (BPD) |
Cynthia McEvoy |
2016-09 | PHASE1; PHASE2 |
| NCT03421730 | COMPLETED | Wheezing; Reactive Airway Disease; Mild Asthma |
Vectura Limited |
2017-12-18 | PHASE1 |
| NCT03015259 | COMPLETED | Asthma |
Kindeva Drug Delivery |
2016-12-29 | PHASE3 |
| NCT02573233 | COMPLETED | Asthma |
Sanofi |
2016-01-27 | PHASE2 |
| NCT02757209 | COMPLETED | Asthma; COPD |
Consorzio Futuro in Ricerca |
2016-04 | |
| NCT02562924 | COMPLETED | Chronic Sinusitis; Nasal Polyposis |
University of Vermont Medical Center |
2015-11 | |
| NCT02357277 | WITHDRAWN | Osteoporosis |
Columbia University |
2015-03 | PHASE4 |
| NCT02986321 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2016-12-15 | PHASE2 |
| NCT02224157 | COMPLETED | Asthma |
AstraZeneca |
2014-11-28 | PHASE3 |
| NCT02149199 | COMPLETED | Asthma |
AstraZeneca |
2014-07-07 | PHASE3 |
| NCT02862509 | UNKNOWN | Chronic Frontal Rhinosinusitis; Vertex to Floor Position |
Khon Kaen University |
2015-11 | PHASE2 |
| NCT02446418 | COMPLETED | Asthma |
GlaxoSmithKline |
2015-07-09 | PHASE3 |
| NCT02771717 | UNKNOWN | Asthma |
University of Nottingham |
2016-05 | PHASE4 |
| NCT01209208 | COMPLETED | Lymphocytic Colitis |
Dr. Falk Pharma GmbH |
2010-05 | PHASE3 |
| NCT04032834 | COMPLETED | Asthma |
Vectura Limited |
2017-02-20 | PHASE1 |
| NCT02668861 | UNKNOWN | Chronic Rhinosinusitis With Nasal Polyps |
The First Affiliated Hospital of Shanxi Medical University |
2016-05 | PHASE3 |
| NCT02696850 | COMPLETED | Rhinosinusitis; Chronic Eosinophilic Rhinosinusitis; Allergic Rhinosinusitis |
Washington University School of Medicine |
2016-01-01 | PHASE4 |
| NCT02941510 | WITHDRAWN | Altitude Sickness |
University of Colorado, Denver |
2017-03-06 | PHASE3 |
| NCT03028701 | COMPLETED | Copd |
Neutec Ar-Ge San ve Tic A.Ş |
2015-09 | PHASE4 |
| NCT02550418 | COMPLETED | Colitis, Ulcerative |
Dr. Falk Pharma GmbH |
2015-10 | PHASE2 |
| NCT02934945 | UNKNOWN | Bronchial Asthma |
Zhujiang Hospital |
2015-09 | PHASE4 |
| NCT03687515 | COMPLETED | Chronic Rhinosinusitis With Polyposis |
Beijing Tongren Hospital |
2015-01-01 | PHASE3 |
| NCT02187445 | COMPLETED | Sickle Cell Disease; Asthma; Acute Chest Syndrome |
Vanderbilt University |
2014-06 | PHASE1 |
| NCT02725242 | COMPLETED | Asthma |
Hat Yai Medical Education Center |
2016-03 | PHASE3 |
| NCT04077892 | COMPLETED | Allergic Rhinitis |
Beijing Tongren Hospital |
2016-06-01 | EARLY_PHASE1 |
| NCT02604173 | COMPLETED | Acute Mountain Sickness |
Stanford University |
2016-08 | PHASE3 |
| NCT02533505 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2015-08-25 | PHASE4 |
| NCT02434029 | COMPLETED | Eosinophilic Esophagitis |
Dr. Falk Pharma GmbH |
2015-11-11 | PHASE3 |
| NCT02425813 | WITHDRAWN | Acute Graft Versus Host Disease; Intestinal Graft Versus Host Disease |
Wake Forest University Health Sciences |
2015-10 | PHASE2 |
| NCT02811016 | COMPLETED | Acute Mountain Sickness |
Salzburger Landeskliniken |
2016-06 | PHASE1 |
| NCT02504801 | UNKNOWN | Post Operative Complication, Pulmonary; Lung Cancer; COPD |
Xiuyi Zhi |
2015-07 | PHASE4 |
| NCT01973751 | UNKNOWN | Asthma |
Tongji Hospital |
2013-11 | |
| NCT02800824 | COMPLETED | Healthy |
Padagis LLC |
PHASE1 | |
| NCT02574975 | UNKNOWN | Asthma |
Zhujiang Hospital |
2015-04 | PHASE4 |
| NCT02526758 | UNKNOWN | Pulmonary Disease，Chronic Obstructive; |
Zhujiang Hospital |
2015-04 | PHASE4 |
| NCT02345161 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2015-01-23 | PHASE3 |
| NCT02715167 | UNKNOWN | Healthy |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2016-03 | |
| NCT02091986 | COMPLETED | Asthma |
AstraZeneca |
2014-04 | PHASE3 |
| NCT03073057 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2016-01 | PHASE1 |
| NCT01520688 | COMPLETED | Asthma |
West Penn Allegheny Health System |
2012-02 | PHASE4 |
| NCT02055352 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2014-05-30 | PHASE4 |
| NCT02233803 | COMPLETED | Asthma |
GlaxoSmithKline |
2014-11-14 | PHASE4 |
| NCT02422121 | COMPLETED | Asthma |
Revalesio Corporation |
2015-04 | PHASE2 |
| NCT02352168 | COMPLETED | Allergic Rhinitis; Inflammation; Respiratory Tract Diseases; Hypersensitivity |
Guangzhou Institute of Respiratory Disease |
2014-09 | |
| NCT01444430 | COMPLETED | Asthma |
AstraZeneca |
2011-12 | PHASE3 |
| NCT00887263 | COMPLETED | Oral Chronic Graft vs Host Disease |
Dr. Falk Pharma GmbH |
2009-03 | PHASE3 |
| NCT01253473 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
National Jewish Health |
2012-04 | PHASE4 |
| NCT01912872 | TERMINATED | Severe IgE-mediated Asthma |
Novartis Pharmaceuticals |
2013-11-11 | PHASE4 |
| NCT01966783 | COMPLETED | Proctitis |
Dr. Falk Pharma GmbH |
2013-09 | PHASE2 |
| NCT01783821 | COMPLETED | Acute Respiratory Distress Syndrome (ARDS) |
Mayo Clinic |
2013-07 | PHASE2 |
| NCT02194062 | COMPLETED | Sinusitis; Nasal Polyps |
Yale University |
2015-01 | |
| NCT01484691 | COMPLETED | Asthma |
University of California, San Francisco |
2012-01 | |
| NCT02308098 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2014-12 | PHASE3 |
| NCT01857479 | COMPLETED | Allergic Bronchopulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2013-05 | PHASE2; PHASE3 |
| NCT01794780 | COMPLETED | COPD |
Novartis Pharmaceuticals |
2013-02-05 | PHASE4 |
| NCT02062463 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2014-05-28 | PHASE3 |
| NCT02056379 | UNKNOWN | Stridor |
Hospital Israelita Albert Einstein |
2014-03 | |
| NCT01349673 | TERMINATED | Proctitis; Proctosigmoiditis |
Bausch Health Americas, Inc. |
2011-05-31 | PHASE3 |
| NCT01787097 | COMPLETED | Chronic Obstructive Lung Disease |
Imperial College London |
2013-01 | PHASE4 |
| NCT01642212 | COMPLETED | Eosinophilic Esophagitis (EoE) |
Shire |
2012-07-23 | PHASE2 |
| NCT01854515 | UNKNOWN | Respiratory Sounds |
Saeed Abbasi |
2012-03 | |
| NCT01769898 | COMPLETED | Bronchiectasis |
The First Affiliated Hospital of Guangzhou Medical University |
2013-07 | PHASE4 |
| NCT02162784 | COMPLETED | Asthma |
Intech Biopharm Ltd. |
2013-02 | PHASE2 |
| NCT01089647 | COMPLETED | Obstructive Sleep Apnea |
Romaker & Associates |
2010-09 | PHASE3 |
| NCT01602523 | UNKNOWN | Emphysema; Poor Sleep Quality |
Temple University |
2011-03 | PHASE3 |
| NCT01070888 | TERMINATED | Exercise Induced Asthma |
Boston Children's Hospital |
2010-02 | PHASE4 |
| NCT01803555 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2013-07-04 | PHASE3 |
| NCT02409563 | COMPLETED | Allergic Rhinitis |
Istituto per la Ricerca e l'Innovazione Biomedica |
2014-01 | PHASE4 |
| NCT01786070 | UNKNOWN | Respiratory Sounds |
Isfahan University of Medical Sciences |
2011-03 | |
| NCT02125851 | COMPLETED | Eosinophilic Esophagitis |
Walter Reed National Military Medical Center |
2014-01 | |
| NCT01980615 | COMPLETED | Healthy Volunteers |
Pearl Therapeutics, Inc. |
2013-11 | PHASE1 |
| NCT01266772 | UNKNOWN | Bronchial Asthma |
Medical University of Lodz |
2011-01 | PHASE3 |
| NCT01687283 | COMPLETED | Asthma |
GlaxoSmithKline |
2012-09-27 | PHASE3 |
| NCT01814618 | WITHDRAWN | Olfaction Disorders; Sinusitis; Paranasal Sinus Diseases |
University of North Carolina, Chapel Hill |
2013-03 | PHASE2 |
| NCT01532648 | COMPLETED | Ulcerative Colitis |
Bausch Health Americas, Inc. |
2012-01-27 | PHASE3 |
| NCT00859274 | COMPLETED | Asthma |
Kuopio University Hospital |
2009-03 | |
| NCT01849406 | COMPLETED | Snoring |
Ioannis Koutsourelakis |
2013-04 | PHASE1 |
| NCT01907204 | COMPLETED | Sinusitis |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2013-07 | PHASE2; PHASE3 |
| NCT01397890 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2011-07 | PHASE4 |
| NCT01405339 | COMPLETED | Chronic Rhinosinusitis |
St. Paul's Hospital, Canada |
2011-08 | PHASE1; PHASE2 |
| NCT01865500 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Ataturk University |
2013-01 | PHASE4 |
| NCT01008410 | COMPLETED | Proctitis; Proctosigmoiditis |
Bausch Health Americas, Inc. |
2009-11-17 | PHASE3 |
| NCT00849095 | COMPLETED | Asthma |
Università degli Studi di Ferrara |
2009-04 | PHASE3 |
| NCT01846962 | COMPLETED | Eosinophilic Esophagitis |
Azienda Policlinico Umberto I |
2012-11 | PHASE4 |
| NCT01136382 | COMPLETED | Asthma |
AstraZeneca |
2010-07 | PHASE2 |
| NCT01008423 | COMPLETED | Proctitis; Proctosigmoiditis |
Bausch Health Americas, Inc. |
2009-11-20 | PHASE3 |
| NCT01278082 | COMPLETED | Induction and Maintaining Remission of Collagenous Colitis |
Dr. Falk Pharma GmbH |
2008-04 | PHASE3 |
| NCT02165033 | COMPLETED | Asthma |
Intech Biopharm Ltd. |
2012-11 | PHASE1 |
| NCT01415518 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2011-09-01 | PHASE4 |
| NCT00883532 | UNKNOWN | Respiratory Distress Syndrome; Chronic Lung Disease of Prematurity |
China Medical University, China |
2009-04 | PHASE4 |
| NCT01668121 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2012-08 | PHASE1 |
| NCT01351792 | TERMINATED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2011-09 | PHASE3 |
| NCT01593826 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2012-05 | PHASE1 |
| NCT01627158 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2012-06 | PHASE1 |
| NCT01147510 | COMPLETED | Persistent Asthma; Elderly |
Ajou University School of Medicine |
2010-07 | PHASE4 |
| NCT01712854 | TERMINATED | Chronic Obstructive Lung Disease |
Columbia University |
2012-03 | PHASE4 |
| NCT01360021 | COMPLETED | Asthma |
AstraZeneca |
2011-11 | PHASE3 |
| NCT01219738 | COMPLETED | Asthma |
University of Miami |
2008-07 | |
| NCT01270256 | COMPLETED | Perennial Allergic Rhinitis |
University of Chicago |
2011-01 | PHASE4 |
| NCT01560689 | COMPLETED | Bronchiolitis Obliterans; Allogeneic Stem Cell Transplantation |
Assistance Publique - Hôpitaux de Paris |
2008-06 | PHASE2 |
| NCT00624754 | COMPLETED | Obstructive Airway Disease |
Assistance Publique - Hôpitaux de Paris |
2008-03 | PHASE2 |
| NCT01760304 | TERMINATED | Chronic Obstructive Pulmonary Disease (COPD) |
Brigham and Women's Hospital |
2012-01 | PHASE4 |
| NCT01268215 | UNKNOWN | Bronchopulmonary Dysplasia |
East Carolina University |
2010-07 | PHASE2 |
| NCT01257048 | COMPLETED | COPD Method Evaluation; Chronic Obstructive Pulmonary Disease Method Evaluation |
AstraZeneca |
2011-08 | EARLY_PHASE1 |
| NCT01373528 | TERMINATED | Chronic Rhinosinusitis |
Ottawa Hospital Research Institute |
2010-12 | |
| NCT01086553 | COMPLETED | Crohn´s Disease |
Dr. Falk Pharma GmbH |
2009-11 | PHASE3 |
| NCT01524198 | COMPLETED | Status Asthmaticus |
King Saud University |
2010-11 | PHASE2; PHASE3 |
| NCT02165046 | COMPLETED | Asthma; Chronic Obstructive Pulmonary Disease (COPD) |
Intech Biopharm Ltd. |
2012-02 | PHASE1 |
| NCT01225549 | COMPLETED | Asthma |
AstraZeneca |
2010-11 | PHASE2 |
| NCT02024659 | COMPLETED | Nasal Polyps |
Beijing Tongren Hospital |
2010-09 | PHASE2; PHASE3 |
| NCT01136655 | COMPLETED | Asthma |
AstraZeneca |
2010-09 | PHASE2 |
| NCT01457716 | COMPLETED | Healthy |
Orion Corporation, Orion Pharma |
2011-10 | |
| NCT01386996 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2011-07 | PHASE1 |
| NCT01179152 | UNKNOWN | Asthma Exacerbation |
Meir Medical Center |
2010-09 | |
| NCT01200108 | COMPLETED | Asthma |
Activaero GmbH |
2010-03 | PHASE2 |
| NCT01269437 | UNKNOWN | Asthma |
NovaMed Pharmaceuticals Inc. |
2010-12 | PHASE2; PHASE3 |
| NCT01423305 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2011-08 | PHASE1 |
| NCT00961233 | COMPLETED | Eosinophilic Esophagitis |
University of North Carolina, Chapel Hill |
2009-10 | |
| NCT01167010 | COMPLETED | Asthma |
Eurofarma Laboratorios S.A. |
2011-04 | PHASE3 |
| NCT00828230 | TERMINATED | Radiation Proctitis |
Dr. Falk Pharma GmbH |
2008-09 | PHASE2 |
| NCT01219036 | COMPLETED | Asthma |
Liam Heaney |
2008-10 | |
| NCT01121016 | UNKNOWN | Nonasthmatic Eosinophilic Bronchitis |
Guangzhou Medical University |
2010-06 | PHASE4 |
| NCT00450086 | COMPLETED | Collagenous Colitis |
Dr. Falk Pharma GmbH |
2007-03 | PHASE3 |
| NCT00801723 | COMPLETED | Ulcerative Colitis |
Bausch Health Americas, Inc. |
2008-12 | PHASE3 |
| NCT01001364 | COMPLETED | ASTHMA |
Eurofarma Laboratorios S.A. |
2010-02 | PHASE3 |
| NCT01069289 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2010-01 | PHASE3 |
| NCT01293734 | COMPLETED | Bronchial Asthma |
Liaoning University of Traditional Chinese Medicine |
2008-12 | PHASE2 |
| NCT00661973 | WITHDRAWN | Asthma |
Imperial College London |
2008-04 | PHASE4 |
| NCT00728481 | COMPLETED | Eosinophilic Esophagitis; Gastroesophageal Reflux Disease; EE; GERD |
Mayo Clinic |
2008-05 | PHASE2; PHASE3 |
| NCT01329276 | COMPLETED | Chronic Obstructive Pulmonary Disease |
University Hospital, Antwerp |
2010-06 | PHASE4 |
| NCT01676987 | COMPLETED | Asthma |
Ache Laboratorios Farmaceuticos S.A. |
2009-04 | PHASE3 |
| NCT00184171 | TERMINATED | Colitis |
Norwegian University of Science and Technology |
2001-11 | |
| NCT01023516 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2009-11 | PHASE2 |
| NCT00939341 | COMPLETED | Asthma |
AstraZeneca |
2009-07 | PHASE4 |
| NCT01340118 | COMPLETED | Asthma |
Chungbuk National University |
2010-05 | PHASE4 |
| NCT00997477 | WITHDRAWN | Asthma |
Novartis Pharmaceuticals |
2010-06 | PHASE4 |
| NCT00675584 | COMPLETED | Asthma |
Milton S. Hershey Medical Center |
2008-08 | PHASE3 |
| NCT01100112 | COMPLETED | Colitis, Ulcerative |
Bausch Health Americas, Inc. |
2010-02 | PHASE3 |
| NCT00706446 | TERMINATED | Asthma |
Brigham and Women's Hospital |
2008-06 | |
| NCT01186653 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Hull University Teaching Hospitals NHS Trust |
2007-10 | PHASE4 |
| NCT00762073 | COMPLETED | Eosinophilic Esophagitis (EoE) |
Shire |
2009-01-08 | PHASE2 |
| NCT00912171 | COMPLETED | Obstructive Sleep Apnea Syndrome |
University of Bologna |
2009-01 | PHASE4 |
| NCT00964535 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2009-09 | PHASE1; PHASE2 |
| NCT00679380 | COMPLETED | Ulcerative Colitis |
Bausch Health Americas, Inc. |
2008-06 | PHASE3 |
| NCT00624429 | UNKNOWN | Asthma |
Phoenix Children's Hospital |
2008-03 | PHASE4 |
| NCT00733317 | COMPLETED | Asthma; Acute Asthma |
Kecioren Education and Training Hospital |
2007-09 | PHASE4 |
| NCT00588406 | COMPLETED | Asthma |
Northwell Health |
2007-09 | PHASE3 |
| NCT00733473 | COMPLETED | Asthma; Acute Asthma |
Kecioren Education and Training Hospital |
2007-09 | PHASE4 |
| NCT00805285 | TERMINATED | Inflammatory Bowel Disease; Ulcerative Colitis |
University of Maryland, Baltimore |
2008-10 | PHASE2 |
| NCT00638456 | COMPLETED | Eosinophilic Esophagitis |
Ranjan Dohil |
2008-02 | PHASE2 |
| NCT00419744 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2007-01 | PHASE3 |
| NCT00915538 | COMPLETED | Asthma |
Western Sky Medical Research |
2009-07 | PHASE4 |
| NCT00855959 | COMPLETED | Asthma |
AstraZeneca |
2009-02 | PHASE3 |
| NCT00587119 | WITHDRAWN | Primary Biliary Cirrhosis; Autoimmune Hepatitis |
Mayo Clinic |
2007-12 | |
| NCT00442117 | COMPLETED | Asthma |
Organon and Co |
2007-06 | PHASE3 |
| NCT00462592 | COMPLETED | Asthma |
Hamilton Health Sciences Corporation |
2007-03 | PHASE3 |
| NCT01055041 | COMPLETED | Moderate to Severe Persistent Bronchial Asthma |
Government Medical College, Bhavnagar |
2008-12 | |
| NCT00667992 | COMPLETED | Asthma |
AstraZeneca |
2008-04 | PHASE3 |
| NCT00180089 | COMPLETED | Leukemia; Graft-Versus-Host Disease |
Technische Universität Dresden |
2004-01 | PHASE3 |
| NCT00584636 | WITHDRAWN | Asthma |
Phoenix Children's Hospital |
2007-10 | PHASE4 |
| NCT00189436 | COMPLETED | Asthma |
Deborah Gentile |
2003-03 | PHASE4 |
| NCT00483743 | COMPLETED | Copd Bronchitis |
Syntara |
2007-11 | PHASE2 |
| NCT00838214 | COMPLETED | Autoimmune Hepatitis |
Dr. Falk Pharma GmbH |
2001-03 | PHASE2; PHASE3 |
| NCT00634413 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Pulmagen Therapeutics |
2008-02 | PHASE2 |
| NCT00569712 | COMPLETED | Lung Cancer; Precancerous Condition |
British Columbia Cancer Agency |
2007-01 | PHASE1 |
| NCT00522782 | COMPLETED | Asthma |
AAADRS Clinical Research Center |
2007-08 | PHASE4 |
| NCT00633919 | COMPLETED | Allergy |
ALK-Abelló A/S |
2006-07 | PHASE2; PHASE3 |
| NCT00716963 | COMPLETED | Mild Intermittent Asthma |
Hamilton Health Sciences Corporation |
2008-07 | PHASE4 |
| NCT00767221 | COMPLETED | IGA Nephropathy |
Calliditas Therapeutics AB |
2005-10 | PHASE2 |
| NCT00509028 | COMPLETED | Asthma |
AstraZeneca |
2006-12 | PHASE3 |
| NCT00321893 | COMPLETED | Lung Cancer |
National Cancer Institute (NCI) |
2006-01 | PHASE2 |
| NCT00996697 | COMPLETED | COPD |
Brian J Lipworth |
2006-10 | PHASE4 |
| NCT00487773 | COMPLETED | Asthma |
Medical University of Lodz |
2007-09 | PHASE4 |
| NCT00542880 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2007-09 | PHASE4 |
| NCT00747110 | COMPLETED | Colitis, Ulcerative |
Dr. Falk Pharma GmbH |
2007-10 | PHASE3 |
| NCT00489853 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2007-07 | PHASE4 |
| NCT00476099 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2006-12 | PHASE3 |
| NCT00271349 | COMPLETED | Eosinophilic Esophagitis |
Swiss EE Study Group |
2005-12 | PHASE2 |
| NCT00419757 | COMPLETED | Asthma |
AstraZeneca |
2007-01 | PHASE3 |
| NCT00496470 | COMPLETED | Chronic Obstructive Pulmonary Disease, COPD |
AstraZeneca |
2007-05 | PHASE4 |
| NCT00940953 | COMPLETED | Seasonal Allergic Rhinitis |
Ligand Pharmaceuticals |
2008-02 | PHASE2 |
| NCT00300118 | COMPLETED | Crohn's Disease |
Dr. Falk Pharma GmbH |
2004-09 | PHASE3 |
| NCT00217022 | TERMINATED | Lymphocytic Colitis; Diarrhea |
Mayo Clinic |
2003-06 | PHASE2; PHASE3 |
| NCT00380484 | COMPLETED | Asthma |
Children´s Clinic, Randers |
2006-09 | PHASE4 |
| NCT00554970 | COMPLETED | Asthma |
Allergan |
2007-11 | PHASE2 |
| NCT02318043 | COMPLETED | Asthma |
Guangzhou Institute of Respiratory Disease |
2007-01 | |
| NCT00393367 | COMPLETED | Asthma; Acute Asthma; Reactive Airway Exacerbation |
Children's Hospital of Philadelphia |
2006-12 | PHASE4 |
| NCT00135408 | COMPLETED | Malignant Melanoma |
Bristol-Myers Squibb |
2005-12 | PHASE2 |
| NCT00938613 | COMPLETED | Seasonal Allergic Rhinitis |
Ligand Pharmaceuticals |
2007-02 | PHASE2 |
| NCT00327808 | COMPLETED | Asthma |
Syntara |
2006-05 | PHASE2 |
| NCT00180076 | COMPLETED | Collagenous Colitis |
Technische Universität Dresden |
2004-07 | PHASE3 |
| NCT00255255 | COMPLETED | Asthma |
AstraZeneca |
2005-11 | PHASE3 |
| NCT00388739 | WITHDRAWN | Asthma |
Baylor College of Medicine |
2006-11-01 | |
| NCT00319488 | COMPLETED | Asthma; Lung Diseases |
National Heart, Lung, and Blood Institute (NHLBI) |
2004-02 | |
| NCT00159263 | COMPLETED | Asthma |
Imperial College London |
2004-11 | |
| NCT00235911 | COMPLETED | Asthma |
AstraZeneca |
2003-09 | PHASE3 |
| NCT00242411 | COMPLETED | Asthma |
AstraZeneca |
2004-09 | PHASE4 |
| NCT00180050 | COMPLETED | Microscopic Colitis |
Technische Universität Dresden |
2002-01 | PHASE3 |
| NCT00560586 | COMPLETED | Obstructive Sleep Apnea |
University of Louisville |
2004-04 | PHASE4 |
| NCT00233584 | COMPLETED | Asthma |
AstraZeneca |
2001-07 | |
| NCT00627679 | COMPLETED | Asthma |
Allergan |
2005-12 | PHASE1 |
| NCT00202189 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Queen's University |
2005-09 | PHASE4 |
| NCT00238784 | COMPLETED | Asthma |
AstraZeneca |
2004-05 | PHASE3 |
| NCT00413387 | COMPLETED | Bronchial Asthma |
Chiesi Farmaceutici S.p.A. |
2004-09 | PHASE3 |
| NCT00163397 | COMPLETED | Asthma |
AstraZeneca |
2004-01 | PHASE3 |
| NCT00163384 | COMPLETED | Asthma |
AstraZeneca |
2004-01 | PHASE3 |
| NCT00641472 | COMPLETED | Asthma |
AstraZeneca |
2002-10 | PHASE4 |
| NCT00728715 | COMPLETED | Bronchiectasis |
Hospital General de Requena |
2004-01 | |
| NCT00642122 | COMPLETED | Asthma |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00642187 | COMPLETED | Asthma |
AstraZeneca |
2002-07 | PHASE3 |
| NCT00642161 | COMPLETED | Asthma |
AstraZeneca |
2002-11 | PHASE3 |
| NCT00479739 | COMPLETED | Asthma |
GlaxoSmithKline |
2002-11 | PHASE4 |
| NCT00092092 | COMPLETED | Asthma, Bronchial |
Organon and Co |
2002-10 | PHASE4 |
| NCT00641446 | COMPLETED | Asthma |
AstraZeneca |
2001-10 | PHASE4 |
| NCT00641680 | COMPLETED | Seasonal Allergic Rhinitis |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00641212 | COMPLETED | Perennial Allergic Rhinitis |
AstraZeneca |
2000-01 | PHASE4 |
| NCT00641914 | COMPLETED | Asthma |
AstraZeneca |
1996-10 | PHASE4 |
| NCT00641979 | COMPLETED | Seasonal Allergic Rhinitis |
AstraZeneca |
2002-04 | PHASE2 |
| NCT02181335 | COMPLETED | Asthma |
Boehringer Ingelheim |
1998-10 | PHASE3 |
| NCT00140946 | COMPLETED | Asthma |
Organon and Co |
1998-03 | PHASE4 |
| NCT00004842 | COMPLETED | Cholangitis, Sclerosing; Liver Cirrhosis, Biliary |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
1997-05 | PHASE1 |
| NCT00259766 | COMPLETED | Asthma |
AstraZeneca |
2004-04 | PHASE3 |
| NCT00658255 | COMPLETED | Stable Asthma |
AstraZeneca |
2002-10 | PHASE2 |
| NCT00252785 | COMPLETED | Asthma |
AstraZeneca |
2005-10 | PHASE3 |
| NCT00135681 | COMPLETED | Asthma; Lung Diseases |
University of New Mexico |
1996-12 | |
| NCT00005880 | COMPLETED | Lung Cancer |
British Columbia Cancer Agency |
2000-07 | PHASE2 |
| NCT00646594 | COMPLETED | Asthma |
AstraZeneca |
2003-11 | PHASE3 |
| NCT00471809 | TERMINATED | Asthma |
National Heart, Lung, and Blood Institute (NHLBI) |
2006-03 | PHASE4 |
| NCT00259779 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2005-09 | PHASE3 |
| NCT00234390 | COMPLETED | Asthma |
AstraZeneca |
1998-11 | PHASE4 |
| NCT00646009 | COMPLETED | Asthma |
AstraZeneca |
2003-03 | PHASE3 |
| NCT00646620 | COMPLETED | Asthma |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00338910 | COMPLETED | Healthy |
University Hospital Tuebingen |
2006-05 | PHASE4 |
| NCT00139165 | UNKNOWN | Collagenous Colitis |
Bonderup, Ole K., M.D. |
2004-09 | PHASE3 |
| NCT00272753 | COMPLETED | Asthma |
AstraZeneca |
2004-04 | PHASE4 |
| NCT00128739 | COMPLETED | Graft Vs Host Disease |
Rafa Laboratories |
2001-01 | PHASE3 |
| NCT00490243 | COMPLETED | Asthma |
Medical University of Lodz |
2003-07 | PHASE4 |
| NCT00646529 | COMPLETED | Asthma |
AstraZeneca |
2002-07 | PHASE3 |
| NCT00652002 | COMPLETED | Asthma |
AstraZeneca |
2002-07 | PHASE3 |
| NCT00252824 | COMPLETED | Asthma |
AstraZeneca |
2005-07 | PHASE3 |
| NCT00206154 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2005-04 | PHASE3 |
| NCT00379028 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2006-09 | PHASE4 |
| NCT00449501 | COMPLETED | Asthma |
AstraZeneca |
2007-03 | PHASE3 |
| NCT00206167 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2005-04 | PHASE3 |
| NCT00651651 | COMPLETED | Asthma |
AstraZeneca |
2002-08 | PHASE3 |
| NCT00232674 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
1999-07 | PHASE4 |
| NCT00244608 | COMPLETED | Asthma |
AstraZeneca |
2005-05 | PHASE3 |
| NCT00146497 | TERMINATED | Premature Infants; Respiratory Distress Syndrome; Chronic Lung Disease; Bronchoalveolar Lavage Fluid; Cytokines |
China Medical University Hospital |
2004-08 | PHASE4 |
| NCT00691951 | COMPLETED | Asthma |
Laval University |
PHASE3 | |
| NCT00326053 | COMPLETED | Asthma |
AstraZeneca |
2006-05 | PHASE3 |
| NCT00239278 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2001-01 | PHASE2 |
| NCT00449527 | COMPLETED | Asthma |
AstraZeneca |
2007-03 | PHASE3 |
| NCT00646516 | COMPLETED | Mild or Moderate Asthma |
AstraZeneca |
2003-10 | PHASE3 |
| NCT00504062 | COMPLETED | Asthma |
AstraZeneca |
2006-10 | PHASE3 |
| NCT00975754 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2009-09 | PHASE1 |
| NCT00252863 | COMPLETED | Asthma |
AstraZeneca |
2004-12 | PHASE3 |
| NCT00259792 | COMPLETED | Asthma |
AstraZeneca |
2004-09 | PHASE3 |
| NCT00554710 | COMPLETED | Crohn's Disease |
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW |
2001-05 | PHASE4 |
| NCT00385593 | TERMINATED | Asthma, Bronchial |
AstraZeneca |
2006-09 | PHASE3 |
| NCT00228475 | COMPLETED | Asthma |
AstraZeneca |
2004-09 | PHASE4 |
| NCT00421122 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2006-09 | PHASE3 |
| NCT00651547 | COMPLETED | Asthma |
AstraZeneca |
2002-07 | PHASE3 |
| NCT00646321 | COMPLETED | Asthma |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00290264 | COMPLETED | Asthma |
AstraZeneca |
2004-12 | PHASE3 |
| NCT00319306 | COMPLETED | Asthma |
AstraZeneca |
2005-09 | PHASE3 |
| NCT00117182 | COMPLETED | Lung Diseases, Obstructive |
Syntara |
2005-07 | PHASE2 |
| NCT00651768 | COMPLETED | Asthma |
AstraZeneca |
2003-08 | PHASE3 |
| NCT00463866 | COMPLETED | Asthma |
AstraZeneca |
2007-03 | PHASE4 |
| NCT00175747 | COMPLETED | Lung Cancer |
University of British Columbia |
2000-01 | PHASE2; PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-08-07)
Check the
Budesonide
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.